Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;92(3):329-338.
doi: 10.1002/jmv.25644. Epub 2019 Dec 9.

Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate

Yoshihito Uchida  1 , Masamitsu Nakao  1 , Shohei Tsuji  1 , Hayato Uemura  1 , Jun-Ichi Kouyama  1 , Kayoko Naiki  1 , Daisuke Motoya  1 , Kayoko Sugawara  1 , Nobuaki Nakayama  1 , Yukinori Imai  1 , Tomoaki Tomiya  1 , Satoshi Mochida  1
Affiliations

Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate

Yoshihito Uchida et al. J Med Virol. 2020 Mar.

Erratum in

Abstract

The significance of switching of the nucleos(t)ide analog used to treat patients with hepatitis B virus (HBV) from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) is uncertain. The subjects of this study were 159 patients with HBV who received treatment with ETV followed by TAF. Among these patients, serial changes in the HBV marker levels were monitored in 92 patients in whom the serum HBsAg levels were ≥100 IU/mL during the 48-week period immediately before and after the switching. A questionnaire survey for medication compliance was performed in 127 patients. The serum HBsAg levels (log IU/mL) decreased by 0.041 during the ETV treatment period and by 0.068 during the TAF administration period. The degree of reduction was higher during the TAF administration period than during the ETV administration period in patients without cirrhosis (P = .030), patients with genotype B HBV (P = .014), and patients with undetectable serum HBcrAg (P = .038). Multivariate analysis revealed the HBV genotype (B vs C; odds ratio, 3.400; P = .025) and serum aspartate aminotransferase level (every 1+; 1.111; P = .015) at the time of switching as factors influencing the treatment efficacy. Thirty-six patients (28%) responded that the number of days that they forgot to take the drug decreased after the drug switching, and 77 patients (61%) reported feeling satisfied with the drug switching. Switching of the nucleos(t)ide analog used from ETV to TAF may be useful in the treatment of patients with HBV infection, as it is associated with both a decrease in the serum HBsAg level and improvement of the medication compliance.

Keywords: HBs-antigen; entecavir; medication compliance; tenofovir alafenamide fumarate.

PubMed Disclaimer

References

REFERENCES

    1. World Health Organization. Global newsroom media centre: fact sheets, hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed July 5, 2019.
    1. Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med. 2004;350:1118-1129.
    1. Kudo M, Izumi N, Ichida T, et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016;46:372-390.
    1. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44:102-107.
    1. Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350-360.

MeSH terms

LinkOut - more resources